Head-to-head decision matrix
Cross-platform buyer history for multi-marketplace resellers best fits the Operator Builder (54/100 fit), while GLP-1 pharmacy index best fits the Research Strategist (36/100 fit). Choose by the founder advantage you can actually bring to the first validation sprint.
Resellers selling the same inventory across eBay, Poshmark, and Mercari have no unified view of a buyer's history, so they cannot spot repeat customers, serial returners, or VIPs across platforms.
Even after the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), patients still hit localized stockouts of specific doses and face cash prices that swing from roughly $199 to $1,000+ per month depending on whether they buy via LillyDirect, NovoCare, Costco, Walmart, or a retail pharmacy. There is no neutral, normalized, machine-readable index that tracks dose-level availability and the cheapest legitimate price for a given drug, dose, and ZIP at a point in time.
Validation criteria
Bars use the existing report visual scale, with each criterion scored out of 10.
Demand looks thin because the report has 2 source-backed signal(s), an editorial confidence of 58/100, and a defined buyer in E-commerce reseller tools.
Demand looks thin because the report has 4 source-backed signal(s), an editorial confidence of 55/100, and a defined buyer in US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels..
Problem severity is thin when the buyer pain, customer value, and dream-outcome scores are combined.
Problem severity is thin when the buyer pain, customer value, and dream-outcome scores are combined.
Willingness to pay is weak; the model has a monetization hypothesis, but it must still be proven through paid pilots or explicit pricing objections.
Willingness to pay is weak; the model has a monetization hypothesis, but it must still be proven through paid pilots or explicit pricing objections.
Competitive room is reduced by 1 recorded alternative(s); the wedge must stay narrow and differentiated.
Competitive room is reduced by 3 recorded alternative(s); the wedge must stay narrow and differentiated.
Feasibility is strong for a low build if the MVP is limited to the first measurable workflow.
Feasibility is weak for a high build if the MVP is limited to the first measurable workflow.
Revenue: $250K-$2M ARR potential if the wedge proves budget urgency and becomes a recurring workflow.
GTM: Start with manual concierge output, direct outreach, and community proof before paid acquisition.
Execution: Execution is low; the main constraint is staying narrow enough for a first proof loop.
Revenue: $250K-$2M ARR potential if the wedge proves budget urgency and becomes a recurring workflow.
GTM: Start with manual concierge output, direct outreach, and community proof before paid acquisition.
Execution: Execution is high; the main constraint is staying narrow enough for a first proof loop.
Cross-platform buyer history for multi-marketplace resellers best fits the Operator Builder (54/100 fit), while GLP-1 pharmacy index best fits the Research Strategist (36/100 fit). Choose by the founder advantage you can actually bring to the first validation sprint.